摘要
目的分析奥利司他联合西格列汀二甲双胍对肥胖型2型糖尿病患者稳态模型胰岛素抵抗指数(HOMA-IR)、稳态模型胰岛β细胞功能指数(HOMA-β)的影响。方法将86例肥胖型2型糖尿病患者按随机数字表法分组,每组43例。对照组以西格列汀二甲双胍治疗,观察组在对照组基础上加奥利司他口服,比较两组治疗效果、血糖指标等。结果对照组、观察组治疗总有效率分别为76.74%、93.02%,组间比较差异有统计学意义(P<0.05);治疗后与对照组比,观察组空腹血糖、餐后2 h血糖水平显著下降,同时总胆固醇、三酰甘油水平明显降低(P<0.05),高密度脂蛋白明显升高(P<0.05)。治疗后,观察组稳态模型胰岛素抵抗指数明显低于对照组,稳态模型胰岛β细胞功能指数明显高于对照组(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论奥利司他联合西格列汀二甲双胍对肥胖型2型糖尿病患者疗效显著,能有效改善血糖、血脂指标,且可改善胰岛β细胞功能,减轻机体的胰岛素抵抗情况。
Objective To analyze the effects of orlistat capsule combined with sigliptin and metformin tablets on HOMA-IR and HOMA-beta in obese type 2 diabetes mellitus.Methods A total of 86 cases of obese type 2 diabetes mellitus were randomly divided into two groups,43 cases in each group.The control group was treated with Sigliptin Metformin Tablets.The observation group was treated with Orlistat Capsules on the basis of the control group.The therapeutic effect and blood sugar index of the two groups were compared.Results The total effective rates of the control group and the observation group were 76.74% and 93.02%,with significant difference between the two groups(P<0.05).After treatment,the levels of fasting blood glucose and 2 h postprandial blood glucose in the observation group decreased significantly,while the levels of total cholesterol and triglyceride decreased significantly(P<0.05),and high density lipoprotein increased significantly(P<0.05).After treatment,the insulin resistance index of the steady-state model in the observation group was significantly lower than that in the control group,and the function index of islet beta cells in the steady-state model was significantly higher than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Olistat Capsule combined with Sigliptin and Metformin Tablets has a significant effect on obese type 2 diabetes mellitus.It can effectively improve blood sugar,lipid index,the function of islet beta cells and reduce insulin resistance.
作者
俞兰
陈晓燕
谢小莉
杨靖靖
钟祥
何家露
凌迎春
钱华
Yu Lan;Chen Xiaoyan;Xie Xiaoli;Yang Jingjing;Zhong Xiang;He Jialu;Ling Yingchun;Qian Hua(Department of Pharmaceutical,Shaoxing Seventh People′s Hospital,Shaoxing 312000,China)
出处
《中国临床保健杂志》
CAS
2019年第6期790-793,共4页
Chinese Journal of Clinical Healthcare
基金
浙江省医药卫生科技计划项目(2019KY723)